CSAD

Across TCGA pan-cancer cohorts, CSAD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CSAD data layer compared with 29 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CSAD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CSAD expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where CSAD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	0.890	0.495	<.001	53	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.758	.008	31	view →
PDAC	DFS	Median	II,III,IV	0.262	0.713	.001	26	view →
LSCC	OS	Median	III,IV	0.483	0.808	.026	4	view →
LUAD	OS	Quartile	All	0.972	0.762	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CSAD–HNSC (DFS)

Open the HNSC breakdown →